Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.71 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | KIF23 | Q02241 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494990 | 1.00 | KIF11 (0.71) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL3494994 | 1.00 | KIF11 (0.71) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL3492860 | 0.95 | KIF11 (0.64) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL3492856 | 0.95 | KIF11 (0.64) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL3494844 | 0.94 | KIF11 (0.73) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL3494839 | 0.94 | KIF11 (0.73) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL1042594 | 0.93 | KIF11 (0.72) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL1042081 | 0.93 | KIF11 (0.72) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL1041038 | 0.93 | KIF11 (0.69) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 | |
| SCHEMBL3494501 | 0.93 | KIF11 (0.69) | KIF11MAP1LC3BCYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093767-A1 | Mitotic Kinase Inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | claimed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | claimed |
| EP-1807399-A2 | INDOLE AND BENZIMIDAZOLE DERIVATIVES | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006060737-A2 | MITOTIC KINESIN INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006049835-A2 | INDOLE AND BENZIMIDAZOLE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-05-11 | — | — | WO | claimed |
| US-20060084687-A1 | Indole and benzimidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2006-04-20 | — | — | US | claimed |
| US-8008335-B2 | Indole and benzimidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008335-B2 | Indole and benzimidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2275412-A1 | Indole and benzimidazole derivatives | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100093767-A1 | Mitotic Kinase Inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093767-A1 | Mitotic Kinase Inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093767-A1 | Mitotic Kinase Inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | CHIRON CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-7064136-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-06-20 | — | — | US | disclosed |
| WO-2006060737-A2 | MITOTIC KINESIN INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| US-20060084687-A1 | Indole and benzimidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084687-A1 | Indole and benzimidazole derivatives | IDO1, IDO2, AADAC | KIF11 2578/4885MAP1LC3B 2958/4885CYP3A4 7/4885 |
| US-20080317744-A1 | Indole and Benzimidazole Derivatives | IDO1, IDO2, AADAC | KIF11 2578/4885MAP1LC3B 2958/4885CYP3A4 7/4885 |
| US-20100093767-A1 | Mitotic Kinase Inhibitors | BUB1B, BUB1, PLK1 | KIF11 18/4885MAP1LC3B 218/4885CYP3A4 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.